Published in Cancer Chemother Pharmacol on January 08, 2010
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol (2015) 1.69
Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS One (2010) 1.29
The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine. Haematologica (2010) 1.09
Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks. Oncotarget (2010) 1.06
Targeting the transposase domain of the DNA repair component Metnase to enhance chemotherapy. Cancer Res (2012) 1.01
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia. Haematologica (2014) 0.94
Novel N-2-(Furyl)-2-(chlorobenzyloxyimino) Ethyl Piperazinyl Quinolones: Synthesis, Cytotoxic Evaluation and Structure-Activity Relationship. Iran J Pharm Res (2015) 0.78
Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia. Drugs (2016) 0.78
Targeting acute myeloid leukemia with TP53-independent vosaroxin. Future Oncol (2016) 0.75
Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape. Ther Adv Hematol (2017) 0.75
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev (2006) 15.09
The roles of FLT3 in hematopoiesis and leukemia. Blood (2002) 6.14
How do stem cells find their way home? Blood (2005) 5.13
Drug therapy for acute myeloid leukemia. Blood (2005) 3.74
Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res (2004) 2.37
A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem (1977) 2.32
In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood (2004) 2.03
Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem (1980) 1.58
Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant (2007) 1.47
Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program (2004) 1.46
Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood (2003) 1.46
Structure and function of bone marrow hemopoiesis: mechanisms of response to ionizing radiation exposure. Cancer Biother Radiopharm (2002) 1.30
Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS One (2010) 1.29
Cellular resistance to anthracyclines. Gen Pharmacol (1996) 1.19
The pharmacokinetics of daunomycin in man. Clin Pharmacol Ther (1971) 1.16
Inhibitory effect of 1-beta-D-arabinofuranosylthymine 5'-triphosphate and 1-beta-D-arabinofuranosylcytosine 5'-triphosphate on DNA polymerases from murine cells and oncornavirus. Cancer Res (1978) 1.15
Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent. Drug Metab Dispos (2008) 1.12
Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol Med (2005) 1.12
Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemother Pharmacol (2008) 1.12
Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia (1996) 1.03
Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood (1996) 0.93
Effects of 1-beta-D-arabinofuranosylcytosine incorporation on eukaryotic DNA template function. Mol Pharmacol (1984) 0.91
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. Clin Cancer Res (2010) 0.91
Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 h infusion. Cancer Chemother Pharmacol (1987) 0.90
Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit. Cancer Res (1980) 0.85
Role of DNA breakage in cytotoxicity of doxorubicin, 9-deoxydoxorubicin, and 4-demethyl-6-deoxydoxorubicin in murine leukemia P388 cells. Cancer Res (1989) 0.83
A study of the mechanisms of cytotoxicity of Ara-C on three human leukemic cell lines. Cancer Chemother Pharmacol (1989) 0.79
Mechanism of inhibition of DNA ligase in Ara-C treated cells. Leuk Res (1991) 0.79
Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response. J Natl Cancer Inst (1981) 0.78
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol (2012) 2.13
Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther (2003) 2.07
The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene (2004) 1.78
SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res (2003) 1.53
The STE20 kinase HGK is broadly expressed in human tumor cells and can modulate cellular transformation, invasion, and adhesion. Mol Cell Biol (2003) 1.52
A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res (2008) 1.47
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood (2009) 1.42
Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol (2010) 1.33
Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS One (2010) 1.29
Discovery of a potent and selective aurora kinase inhibitor. Bioorg Med Chem Lett (2008) 1.15
Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent. Drug Metab Dispos (2008) 1.12
Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemother Pharmacol (2008) 1.12
Single-cell network profiling of peripheral blood mononuclear cells from healthy donors reveals age- and race-associated differences in immune signaling pathway activation. J Immunol (2012) 1.10
SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol (2009) 1.08
Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML. Leuk Res (2012) 0.96
SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol (2009) 0.93
Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice. Drug Metab Dispos (2005) 0.93
Successful pregnancy with nocturnal hemodialysis. Am J Kidney Dis (2004) 0.93
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol (2014) 0.93
Characterization of humanized antibodies secreted by Aspergillus niger. Appl Environ Microbiol (2004) 0.91
Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line. Cancer Res (2010) 0.91
Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function. J Clin Pharmacol (2010) 0.91
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. Clin Cancer Res (2010) 0.91
Adventitial microvessel formation after coronary stenting and the effects of SU11218, a tyrosine kinase inhibitor. J Am Coll Cardiol (2006) 0.90
Association between B-cell receptor responsiveness and disease progression in B-cell chronic lymphocytic leukemia: results from single cell network profiling studies. Haematologica (2012) 0.88
Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT). Bioconjug Chem (2006) 0.88
Iron(III)-binding of the anticancer agents doxorubicin and vosaroxin. Dalton Trans (2015) 0.88
Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors. Oncogene (2002) 0.86
2-Aminobenzimidazoles as potent Aurora kinase inhibitors. Bioorg Med Chem Lett (2009) 0.84
Racial differences in B cell receptor signaling pathway activation. J Transl Med (2012) 0.84
Structure-activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists. Bioorg Med Chem Lett (2010) 0.82
Pharmacokinetics of rhuMAb CD18, a recombinant humanised monoclonal antibody fragment to CD18, in normal healthy human volunteers. BioDrugs (2002) 0.81
Improved effect of an antiangiogenic tyrosine kinase inhibitor (SU5416) by combinations with fractionated radiotherapy or low molecular weight heparin. Neoplasia (2003) 0.81
Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists. Bioorg Med Chem Lett (2010) 0.81
Functional pathway analysis using SCNP of FLT3 receptor pathway deregulation in AML provides prognostic information independent from mutational status. PLoS One (2013) 0.79
Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. J Pharmacol Exp Ther (2002) 0.78
Inter-donor variation in cell subset specific immune signaling responses in healthy individuals. Am J Clin Exp Immunol (2012) 0.76
AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin. PLoS One (2013) 0.76
Water-soluble prodrugs of an Aurora kinase inhibitor. Bioorg Med Chem Lett (2009) 0.75